ID   CY24B_HUMAN             Reviewed;         570 AA.
AC   P04839; A8K138; Q2PP16;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   28-JUN-2023, entry version 234.
DE   RecName: Full=Cytochrome b-245 heavy chain;
DE            EC=1.-.-.-;
DE   AltName: Full=CGD91-phox;
DE   AltName: Full=Cytochrome b(558) subunit beta;
DE            Short=Cytochrome b558 subunit beta;
DE   AltName: Full=Heme-binding membrane glycoprotein gp91phox;
DE   AltName: Full=NADPH oxidase 2;
DE   AltName: Full=Neutrophil cytochrome b 91 kDa polypeptide;
DE   AltName: Full=Superoxide-generating NADPH oxidase heavy chain subunit;
DE   AltName: Full=gp91-1;
DE   AltName: Full=gp91-phox;
DE   AltName: Full=p22 phagocyte B-cytochrome;
GN   Name=CYBB {ECO:0000312|HGNC:HGNC:2578}; Synonyms=NOX2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS CGDX ASP-41 AND ARG-537, AND
RP   VARIANTS ARG-364 AND GLU-517.
RX   PubMed=12139950; DOI=10.1006/clim.2002.5230;
RA   Jirapongsananuruk O., Niemela J.E., Malech H.L., Fleisher T.A.;
RT   "CYBB mutation analysis in X-linked chronic granulomatous disease.";
RL   Clin. Immunol. 104:73-76(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-570.
RX   PubMed=2425263; DOI=10.1038/322032a0;
RA   Royer-Pokora B., Kunkel L.M., Monaco A.P., Goff S.C., Newburger P.E.,
RA   Baehner R.L., Cole F.S., Curnutte J.T., Orkin S.H.;
RT   "Cloning the gene for an inherited human disorder -- chronic granulomatous
RT   disease -- on the basis of its chromosomal location.";
RL   Nature 322:32-38(1986).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-135.
RX   PubMed=3600768; DOI=10.1038/327717a0;
RA   Dinauer M.C., Orkin S.H., Brown R., Jesaitis A.J., Parkos C.A.;
RT   "The glycoprotein encoded by the X-linked chronic granulomatous disease
RT   locus is a component of the neutrophil cytochrome b complex.";
RL   Nature 327:717-720(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 233-267.
RC   TISSUE=Peripheral blood;
RX   PubMed=9790760; DOI=10.1006/geno.1998.5510;
RA   Kumatori A., Faizunnessa N.N., Suzuki S., Moriuchi T., Kurozumi H.,
RA   Nakamura M.;
RT   "Nonhomologous recombination between the cytochrome b558 heavy chain gene
RT   (CYBB) and LINE-1 causes an X-linked chronic granulomatous disease.";
RL   Genomics 53:123-128(1998).
RN   [9]
RP   PROTEIN SEQUENCE OF 2-44, AND SUBUNIT.
RX   PubMed=3600769; DOI=10.1038/327720a0;
RA   Teahan C., Rowe P., Parker P., Totty N., Segal A.W.;
RT   "The X-linked chronic granulomatous disease gene codes for the beta-chain
RT   of cytochrome b-245.";
RL   Nature 327:720-721(1987).
RN   [10]
RP   CHARACTERIZATION AS A PROTON CHANNEL.
RX   PubMed=10578014; DOI=10.1085/jgp.114.6.771;
RA   Henderson L.M., Meech R.W.;
RT   "Evidence that the product of the human X-linked CGD gene, gp91-phox, is a
RT   voltage-gated H(+) pathway.";
RL   J. Gen. Physiol. 114:771-786(1999).
RN   [11]
RP   SUBUNIT, PHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=19028840; DOI=10.1096/fj.08-114553;
RA   Raad H., Paclet M.H., Boussetta T., Kroviarski Y., Morel F., Quinn M.T.,
RA   Gougerot-Pocidalo M.A., Dang P.M., El-Benna J.;
RT   "Regulation of the phagocyte NADPH oxidase activity: phosphorylation of
RT   gp91phox/NOX2 by protein kinase C enhances its diaphorase activity and
RT   binding to Rac2, p67phox, and p47phox.";
RL   FASEB J. 23:1011-1022(2009).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-132; ASN-149 AND ASN-240.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   INTERACTION WITH CYBC1, AND SUBCELLULAR LOCATION.
RX   PubMed=28351984; DOI=10.1084/jem.20161382;
RA   Thomas D.C., Clare S., Sowerby J.M., Pardo M., Juss J.K., Goulding D.A.,
RA   van der Weyden L., Storisteanu D., Prakash A., Espeli M., Flint S.,
RA   Lee J.C., Hoenderdos K., Kane L., Harcourt K., Mukhopadhyay S., Umrania Y.,
RA   Antrobus R., Nathan J.A., Adams D.J., Bateman A., Choudhary J.S.,
RA   Lyons P.A., Condliffe A.M., Chilvers E.R., Dougan G., Smith K.G.;
RT   "Eros is a novel transmembrane protein that controls the phagocyte
RT   respiratory burst and is essential for innate immunity.";
RL   J. Exp. Med. 214:1111-1128(2017).
RN   [15]
RP   STRUCTURE BY NMR OF 556-570 IN COMPLEX WITH NCF1, AND INTERACTION WITH
RP   NCF1.
RX   PubMed=9224653; DOI=10.1042/bj3250249;
RA   Adams E.R., Dratz E.A., Gizachew D., Deleo F.R., Yu L., Volpp B.D.,
RA   Vlases M., Jesaitis A.J., Quinn M.T.;
RT   "Interaction of human neutrophil flavocytochrome b with cytosolic proteins:
RT   transferred-NOESY NMR studies of a gp91phox C-terminal peptide bound to
RT   p47phox.";
RL   Biochem. J. 325:249-257(1997).
RN   [16]
RP   INVOLVEMENT IN CGDX, AND VARIANT CGDX HIS-415.
RX   PubMed=2556453; DOI=10.1172/jci114393;
RA   Dinauer M.C., Curnutte J.T., Rosen H.R., Orkin S.H.;
RT   "A missense mutation in the neutrophil cytochrome b heavy chain in
RT   cytochrome-positive X-linked chronic granulomatous disease.";
RL   J. Clin. Invest. 84:2012-2016(1989).
RN   [17]
RP   VARIANTS CGDX ARG-101; THR-156; TYR-209; SER-244 AND ALA-389.
RX   PubMed=1710153;
RA   Bolscher B.G.J.M., de Boer M., de Klein A., Weening R.S., Roos D.;
RT   "Point mutations in the beta-subunit of cytochrome b558 leading to X-linked
RT   chronic granulomatous disease.";
RL   Blood 77:2482-2487(1991).
RN   [18]
RP   VARIANT CGDX GLU-57.
RX   PubMed=8101486; DOI=10.1007/bf01955051;
RA   Ariga T., Sakiyama Y., Tomizawa K., Imajoh-Ohmi S., Kanegasaki S.,
RA   Matsumoto S.;
RT   "A newly recognized point mutation in the cytochrome b558 heavy chain gene
RT   replacing alanine57 by glutamic acid, in a patient with cytochrome b
RT   positive X-linked chronic granulomatous disease.";
RL   Eur. J. Pediatr. 152:469-472(1993).
RN   [19]
RP   VARIANT CGDX HIS-339.
RX   PubMed=7927345; DOI=10.1007/bf00201609;
RA   Ariga T., Sakiyama Y., Matsumoto S.;
RT   "Two novel point mutations in the cytochrome b 558 heavy chain gene,
RT   detected in two Japanese patients with X-linked chronic granulomatous
RT   disease.";
RL   Hum. Genet. 94:441-441(1994).
RN   [20]
RP   VARIANT CGDX GLY-500.
RX   PubMed=8182143; DOI=10.1172/jci117207;
RA   Leusen J.H.W., de Boer M., Bolscher B.G.J.M., Hilarius P.M., Weening R.S.,
RA   Ochs H.D., Roos D., Verhoeven A.J.;
RT   "A point mutation in gp91-phox of cytochrome b558 of the human NADPH
RT   oxidase leading to defective translocation of the cytosolic proteins p47-
RT   phox and p67-phox.";
RL   J. Clin. Invest. 93:2120-2126(1994).
RN   [21]
RP   VARIANTS CGDX ILE-205; PHE-215 DEL AND GLN-342.
RX   PubMed=8916969;
RA   Hui Y.F., Chan S.Y., Lau Y.L.;
RT   "Identification of mutations in seven Chinese patients with X-linked
RT   chronic granulomatous disease.";
RL   Blood 88:4021-4028(1996).
RN   [22]
RP   ERRATUM OF PUBMED:8916969.
RA   Hui Y.F., Chan S.Y., Lau Y.L.;
RL   Blood 89:1843-1843(1996).
RN   [23]
RP   VARIANT CGDX PHE-215 DEL.
RX   PubMed=9111587; DOI=10.1111/j.1600-0609.1997.tb00928.x;
RA   Jendrossek V., Ritzel A., Neubauer B., Heyden S., Gahr M.;
RT   "An in-frame triplet deletion within the gp91-phox gene in an adult X-
RT   linked chronic granulomatous disease patient with residual NADPH-oxidase
RT   activity.";
RL   Eur. J. Haematol. 58:78-85(1997).
RN   [24]
RP   VARIANTS CGDX ARG-20; SER-54; ARG-59; ARG-119; THR-156; GLN-209; ASN-222;
RP   ARG-222; TYR-222; LEU-223; ARG-244; LYS-309; LYS-315 DEL; GLU-322; PHE-325;
RP   PRO-333; HIS-339; PRO-356; ARG-405; GLU-408; ARG-408; HIS-415; LEU-415;
RP   PRO-422; ARG-453; CYS-516; ASP-534 AND ARG-537.
RX   PubMed=9585602; DOI=10.1086/301874;
RA   Rae J., Newburger P.E., Dinauer M.C., Noack D., Hopkins P.J., Kuruto R.,
RA   Curnutte J.T.;
RT   "X-linked chronic granulomatous disease: mutations in the CYBB gene
RT   encoding the gp91-phox component of respiratory-burst oxidase.";
RL   Am. J. Hum. Genet. 62:1320-1331(1998).
RN   [25]
RP   VARIANT CGDX TYR-101.
RX   PubMed=9856476; DOI=10.1007/s004390050836;
RA   Tsuda M., Kaneda M., Sakiyama T., Inana I., Owada M., Kiryu C.,
RA   Shiraishi T., Kakinuma K.;
RT   "A novel mutation at a probable heme-binding ligand in neutrophil
RT   cytochrome b558 in atypical X-linked chronic granulomatous disease.";
RL   Hum. Genet. 103:377-381(1998).
RN   [26]
RP   VARIANTS CGDX ARG-179 AND 298-THR--THR-302 DEL.
RX   PubMed=9794433;
RA   Dusi S., Nadalini K.A., Donini M., Zentilin L., Wientjes F.B., Roos D.,
RA   Giacca M., Rossi F.;
RT   "Nicotinamide-adenine dinucleotide phosphate oxidase assembly and
RT   activation in EBV-transformed B lymphoblastoid cell lines of normal and
RT   chronic granulomatous disease patients.";
RL   J. Immunol. 161:4968-4974(1998).
RN   [27]
RP   VARIANTS CGDX MET-54; ASP-55; GLU-57; HIS-339 AND PHE-344.
RX   PubMed=9667376; DOI=10.1203/00006450-199807000-00014;
RA   Ariga T., Furuta H., Cho K., Sakiyama Y.;
RT   "Genetic analysis of 13 families with X-linked chronic granulomatous
RT   disease reveals a low proportion of sporadic patients and a high proportion
RT   of sporadic carriers.";
RL   Pediatr. Res. 44:85-92(1998).
RN   [28]
RP   VARIANTS CGDX PHE-193; ARG-222; TYR-338; HIS-339 AND PRO-546, AND VARIANT
RP   ARG-364.
RX   PubMed=10089913; DOI=10.1016/s0301-472x(98)00024-1;
RA   Roesler J., Heyden S., Burdelski M., Schaefer H., Kreth H.-W., Lehmann R.,
RA   Paul D., Marzahn J., Gahr M., Roesen-Wolff A.;
RT   "Uncommon missense and splice mutations and resulting biochemical
RT   phenotypes in German patients with X-linked chronic granulomatous
RT   disease.";
RL   Exp. Hematol. 27:505-511(1999).
RN   [29]
RP   VARIANTS CGDX VAL-225 AND TYR-244.
RX   PubMed=9888386;
RX   DOI=10.1002/(sici)1098-1004(1999)13:1<29::aid-humu3>3.0.co;2-x;
RA   Patino P.J., Perez J.E., Lopez J.A., Condino-Neto A., Grumach A.S.,
RA   Botero J.H., Curnutte J.T., Garcia de Olarte D.;
RT   "Molecular analysis of chronic granulomatous disease caused by defects in
RT   gp91-phox.";
RL   Hum. Mutat. 13:29-37(1999).
RN   [30]
RP   VARIANTS CGDX MET-54; ASP-55; GLU-57; TYR-101; ARG-209; GLY-224; LYS-309;
RP   TYR-338; HIS-339; PHE-344; GLU-389; PRO-420 AND ARG-516.
RX   PubMed=10914676; DOI=10.1007/s004390000288;
RA   Ishibashi F., Nunoi H., Endo F., Matsuda I., Kanegasaki S.;
RT   "Statistical and mutational analysis of chronic granulomatous disease in
RT   Japan with special reference to gp91-phox and p22-phox deficiency.";
RL   Hum. Genet. 106:473-481(2000).
RN   [31]
RP   VARIANTS CGDX 54-ARG-ALA-55 DEL; TRP-59; PRO-307 AND ARG-505.
RX   PubMed=11462241; DOI=10.1002/humu.1166;
RA   Gerard B., El Benna J., Alcain F., Gougerot-Pocidalo M.-A., Grandchamp B.,
RA   Chollet-Martin S.;
RT   "Characterization of 11 novel mutations in the X-linked chronic
RT   granulomatous disease (CYBB gene).";
RL   Hum. Mutat. 18:163-163(2001).
RN   [32]
RP   VARIANTS CGDX ASN-303 AND ARG-304.
RX   PubMed=11997083; DOI=10.1016/s0925-4439(01)00110-7;
RA   Stasia M.J., Lardy B., Maturana A., Rousseau P., Martel C., Bordigoni P.,
RA   Demaurex N., Morel F.;
RT   "Molecular and functional characterization of a new X-linked chronic
RT   granulomatous disease variant (X91+) case with a double missense mutation
RT   in the cytosolic gp91phox C-terminal tail.";
RL   Biochim. Biophys. Acta 1586:316-330(2002).
RN   [33]
RP   CHARACTERIZATION OF VARIANTS CGDX ASN-303 AND ARG-304.
RX   PubMed=15338276; DOI=10.1007/s00439-004-1173-z;
RA   Bionda C., Li X.J., van Bruggen R., Eppink M., Roos D., Morel F.,
RA   Stasia M.-J.;
RT   "Functional analysis of two-amino acid substitutions in gp91 phox in a
RT   patient with X-linked flavocytochrome b558-positive chronic granulomatous
RT   disease by means of transgenic PLB-985 cells.";
RL   Hum. Genet. 115:418-427(2004).
RN   [34]
RP   VARIANT CGDX ARG-408.
RX   PubMed=18773283; DOI=10.1007/s10875-008-9243-y;
RA   Bakri F.G., Martel C., Khuri-Bulos N., Mahafzah A., El-Khateeb M.S.,
RA   Al-Wahadneh A.M., Hayajneh W.A., Hamamy H.A., Maquet E., Molin M.,
RA   Stasia M.J.;
RT   "First report of clinical, functional, and molecular investigation of
RT   chronic granulomatous disease in nine Jordanian families.";
RL   J. Clin. Immunol. 29:215-230(2009).
RN   [35]
RP   VARIANTS IMD34 PRO-178 AND PRO-231.
RX   PubMed=21278736; DOI=10.1038/ni.1992;
RA   Bustamante J., Arias A.A., Vogt G., Picard C., Galicia L.B., Prando C.,
RA   Grant A.V., Marchal C.C., Hubeau M., Chapgier A., de Beaucoudrey L.,
RA   Puel A., Feinberg J., Valinetz E., Janniere L., Besse C., Boland A.,
RA   Brisseau J.M., Blanche S., Lortholary O., Fieschi C., Emile J.F.,
RA   Boisson-Dupuis S., Al-Muhsen S., Woda B., Newburger P.E., Condino-Neto A.,
RA   Dinauer M.C., Abel L., Casanova J.L.;
RT   "Germline CYBB mutations that selectively affect macrophages in kindreds
RT   with X-linked predisposition to tuberculous mycobacterial disease.";
RL   Nat. Immunol. 12:213-221(2011).
RN   [36]
RP   VARIANTS CGDX ASP-488 AND GLU-500.
RX   PubMed=22125116; DOI=10.1002/humu.22003;
RA   Boog B., Quach A., Costabile M., Smart J., Quinn P., Singh H., Gold M.,
RA   Booker G., Choo S., Hii C.S., Ferrante A.;
RT   "Identification and functional characterization of two novel mutations in
RT   the alpha-helical loop (residues 484-503) of CYBB/gp91(phox) resulting in
RT   the rare X91(+) variant of chronic granulomatous disease.";
RL   Hum. Mutat. 33:471-475(2012).
RN   [37]
RP   VARIANTS CGDX ASN-299; ASP-338; HIS-339; PHE-344 AND GLU-412.
RX   PubMed=23910690; DOI=10.1016/j.jaci.2013.05.039;
RA   Koker M.Y., Camcioglu Y., van Leeuwen K., Kilic S.S., Barlan I., Yilmaz M.,
RA   Metin A., de Boer M., Avcilar H., Patiroglu T., Yildiran A., Yegin O.,
RA   Tezcan I., Sanal O., Roos D.;
RT   "Clinical, functional, and genetic characterization of chronic
RT   granulomatous disease in 89 Turkish patients.";
RL   J. Allergy Clin. Immunol. 132:1156-1163(2013).
RN   [38]
RP   VARIANT CGDX GLY-409.
RX   PubMed=27666509; DOI=10.1016/j.micpath.2016.09.020;
RA   Khan T.A., Kalsoom K., Iqbal A., Asif H., Rahman H., Farooq S.O.,
RA   Naveed H., Nasir U., Amin M.U., Hussain M., Tipu H.N., Florea A.;
RT   "A novel missense mutation in the NADPH binding domain of CYBB abolishes
RT   the NADPH oxidase activity in a male patient with increased susceptibility
RT   to infections.";
RL   Microb. Pathog. 100:163-169(2016).
CC   -!- FUNCTION: Critical component of the membrane-bound oxidase of
CC       phagocytes that generates superoxide. It is the terminal component of a
CC       respiratory chain that transfers single electrons from cytoplasmic
CC       NADPH across the plasma membrane to molecular oxygen on the exterior.
CC       Also functions as a voltage-gated proton channel that mediates the H(+)
CC       currents of resting phagocytes. It participates in the regulation of
CC       cellular pH and is blocked by zinc.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692; Evidence={ECO:0000305};
CC   -!- SUBUNIT: Composed of a heavy chain (beta) and a light chain (alpha).
CC       Component of an NADPH oxidase complex composed of a heterodimer formed
CC       by the membrane proteins CYBA and CYBB and the cytosolic subunits NCF1,
CC       NCF2 and NCF4. Interacts with NCF1. Interacts with calprotectin
CC       (S100A8/9). Interacts with NRROS; the interaction is direct and impairs
CC       formation of a stable NADPH oxidase complex (PubMed:19028840,
CC       PubMed:3600769, PubMed:9224653). Interacts with CYBC1; CYBC1 may act as
CC       a chaperone stabilizing Cytochrome b-245 heterodimer (PubMed:28351984).
CC       Interacts with NCF2; the interaction is enhanced in the presence of
CC       GBP7 (By similarity). The CYBA-CYBB complex interacts with GBP7 (By
CC       similarity). {ECO:0000250|UniProtKB:Q61093,
CC       ECO:0000269|PubMed:19028840, ECO:0000269|PubMed:28351984,
CC       ECO:0000269|PubMed:3600769, ECO:0000269|PubMed:9224653}.
CC   -!- INTERACTION:
CC       P04839; Q9BQA9: CYBC1; NbExp=3; IntAct=EBI-6253630, EBI-2680384;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Note=As unassembled monomer may localize to the endoplasmic reticulum.
CC       {ECO:0000305|PubMed:28351984}.
CC   -!- TISSUE SPECIFICITY: Detected in neutrophils (at protein level).
CC       {ECO:0000269|PubMed:19028840}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:19159218}.
CC   -!- PTM: Phosphorylated on Ser and Thr residues.
CC       {ECO:0000269|PubMed:19028840}.
CC   -!- PTM: Undergoes 'Lys-48'-linked polyubiquitination, likely by RNF145,
CC       triggering endoplasmic reticulum-associated degradation.
CC       {ECO:0000250|UniProtKB:Q61093}.
CC   -!- DISEASE: Granulomatous disease, chronic, X-linked (CGDX) [MIM:306400]:
CC       A form of chronic granulomatous disease, a primary immunodeficiency
CC       characterized by severe recurrent bacterial and fungal infections,
CC       along with manifestations of chronic granulomatous inflammation. It
CC       results from an impaired ability of phagocytes to mount a burst of
CC       reactive oxygen species in response to pathogens.
CC       {ECO:0000269|PubMed:10089913, ECO:0000269|PubMed:10914676,
CC       ECO:0000269|PubMed:11462241, ECO:0000269|PubMed:11997083,
CC       ECO:0000269|PubMed:12139950, ECO:0000269|PubMed:15338276,
CC       ECO:0000269|PubMed:1710153, ECO:0000269|PubMed:18773283,
CC       ECO:0000269|PubMed:22125116, ECO:0000269|PubMed:23910690,
CC       ECO:0000269|PubMed:2556453, ECO:0000269|PubMed:27666509,
CC       ECO:0000269|PubMed:7927345, ECO:0000269|PubMed:8101486,
CC       ECO:0000269|PubMed:8182143, ECO:0000269|PubMed:8916969,
CC       ECO:0000269|PubMed:9111587, ECO:0000269|PubMed:9585602,
CC       ECO:0000269|PubMed:9667376, ECO:0000269|PubMed:9794433,
CC       ECO:0000269|PubMed:9856476, ECO:0000269|PubMed:9888386}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Immunodeficiency 34 (IMD34) [MIM:300645]: A form of Mendelian
CC       susceptibility to mycobacterial disease, a rare condition characterized
CC       by predisposition to illness caused by moderately virulent
CC       mycobacterial species, such as Bacillus Calmette-Guerin (BCG) vaccine,
CC       environmental non-tuberculous mycobacteria, and by the more virulent
CC       Mycobacterium tuberculosis. Other microorganisms rarely cause severe
CC       clinical disease in individuals with susceptibility to mycobacterial
CC       infections, with the exception of Salmonella which infects less than
CC       50% of these individuals. {ECO:0000269|PubMed:21278736}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA27635.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA29327.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=CYBBbase; Note=CYBB deficiency database;
CC       URL="http://structure.bmc.lu.se/idbase/CYBBbase/";
CC   -!- WEB RESOURCE: Name=Mendelian genes cytochrome b-245, beta polypeptide
CC       (CYBB); Note=Leiden Open Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/CYBB";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X04011; CAA27635.1; ALT_INIT; mRNA.
DR   EMBL; AF469769; AAL76082.1; -; Genomic_DNA.
DR   EMBL; AF469757; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469758; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469759; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469760; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469761; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469762; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469763; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469764; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469765; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469766; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469767; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; AF469768; AAL76082.1; JOINED; Genomic_DNA.
DR   EMBL; DQ314869; ABC40728.1; -; Genomic_DNA.
DR   EMBL; AK289753; BAF82442.1; -; mRNA.
DR   EMBL; CH471141; EAW59453.1; -; Genomic_DNA.
DR   EMBL; BC032720; AAH32720.1; -; mRNA.
DR   EMBL; X05895; CAA29327.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AB013904; BAA34183.1; -; Genomic_DNA.
DR   CCDS; CCDS14242.1; -.
DR   PIR; S70773; S70773.
DR   RefSeq; NP_000388.2; NM_000397.3.
DR   PDB; 3A1F; X-ray; 2.00 A; A=385-570.
DR   PDB; 7U8G; EM; 3.20 A; A=2-570.
DR   PDB; 8GZ3; EM; 3.30 A; B=1-570.
DR   PDBsum; 3A1F; -.
DR   PDBsum; 7U8G; -.
DR   PDBsum; 8GZ3; -.
DR   AlphaFoldDB; P04839; -.
DR   SMR; P04839; -.
DR   BioGRID; 107916; 19.
DR   ComplexPortal; CPX-1017; Phagocyte NADPH oxidase complex, RAC1 variant.
DR   ComplexPortal; CPX-6134; Phagocyte NADPH oxidase complex, RAC2 variant.
DR   ComplexPortal; CPX-6135; Phagocyte NADPH oxidase complex, RAC3 variant.
DR   DIP; DIP-42005N; -.
DR   IntAct; P04839; 4.
DR   STRING; 9606.ENSP00000367851; -.
DR   BindingDB; P04839; -.
DR   ChEMBL; CHEMBL1287627; -.
DR   DrugBank; DB00514; Dextromethorphan.
DR   GuidetoPHARMACOLOGY; 3002; -.
DR   PeroxiBase; 5962; HsNOx02.
DR   TCDB; 5.B.1.1.1; the phagocyte (gp91(phox)) nadph oxidase family.
DR   GlyConnect; 1165; 2 N-Linked glycans (1 site).
DR   GlyCosmos; P04839; 3 sites, 2 glycans.
DR   GlyGen; P04839; 6 sites, 2 N-linked glycans (1 site).
DR   iPTMnet; P04839; -.
DR   PhosphoSitePlus; P04839; -.
DR   SwissPalm; P04839; -.
DR   BioMuta; CYBB; -.
DR   DMDM; 115211; -.
DR   CPTAC; CPTAC-1181; -.
DR   CPTAC; CPTAC-1203; -.
DR   EPD; P04839; -.
DR   jPOST; P04839; -.
DR   MassIVE; P04839; -.
DR   MaxQB; P04839; -.
DR   PaxDb; P04839; -.
DR   PeptideAtlas; P04839; -.
DR   PRIDE; P04839; -.
DR   ProteomicsDB; 51748; -.
DR   ABCD; P04839; 1 sequenced antibody.
DR   Antibodypedia; 24864; 556 antibodies from 40 providers.
DR   DNASU; 1536; -.
DR   Ensembl; ENST00000378588.5; ENSP00000367851.4; ENSG00000165168.9.
DR   GeneID; 1536; -.
DR   KEGG; hsa:1536; -.
DR   MANE-Select; ENST00000378588.5; ENSP00000367851.4; NM_000397.4; NP_000388.2.
DR   UCSC; uc004ddr.3; human.
DR   AGR; HGNC:2578; -.
DR   CTD; 1536; -.
DR   DisGeNET; 1536; -.
DR   GeneCards; CYBB; -.
DR   GeneReviews; CYBB; -.
DR   HGNC; HGNC:2578; CYBB.
DR   HPA; ENSG00000165168; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MalaCards; CYBB; -.
DR   MIM; 300481; gene.
DR   MIM; 300645; phenotype.
DR   MIM; 306400; phenotype.
DR   neXtProt; NX_P04839; -.
DR   OpenTargets; ENSG00000165168; -.
DR   Orphanet; 379; Chronic granulomatous disease.
DR   Orphanet; 319623; X-linked mendelian susceptibility to mycobacterial diseases due to CYBB deficiency.
DR   PharmGKB; PA27076; -.
DR   VEuPathDB; HostDB:ENSG00000165168; -.
DR   eggNOG; KOG0039; Eukaryota.
DR   GeneTree; ENSGT00940000160244; -.
DR   HOGENOM; CLU_005646_3_1_1; -.
DR   InParanoid; P04839; -.
DR   OMA; FTFAKEH; -.
DR   OrthoDB; 367877at2759; -.
DR   PhylomeDB; P04839; -.
DR   TreeFam; TF105354; -.
DR   PathwayCommons; P04839; -.
DR   Reactome; R-HSA-1222556; ROS and RNS production in phagocytes.
DR   Reactome; R-HSA-1236973; Cross-presentation of particulate exogenous antigens (phagosomes).
DR   Reactome; R-HSA-3299685; Detoxification of Reactive Oxygen Species.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   SignaLink; P04839; -.
DR   SIGNOR; P04839; -.
DR   BioGRID-ORCS; 1536; 9 hits in 778 CRISPR screens.
DR   ChiTaRS; CYBB; human.
DR   GeneWiki; CYBB; -.
DR   GenomeRNAi; 1536; -.
DR   Pharos; P04839; Tchem.
DR   PRO; PR:P04839; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P04839; protein.
DR   Bgee; ENSG00000165168; Expressed in monocyte and 171 other tissues.
DR   ExpressionAtlas; P04839; baseline and differential.
DR   Genevisible; P04839; HS.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0043020; C:NADPH oxidase complex; IDA:BHF-UCL.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005635; C:nuclear envelope; IEA:Ensembl.
DR   GO; GO:0097038; C:perinuclear endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IMP:BHF-UCL.
DR   GO; GO:0020037; F:heme binding; IMP:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0016175; F:superoxide-generating NAD(P)H oxidase activity; TAS:BHF-UCL.
DR   GO; GO:0005244; F:voltage-gated monoatomic ion channel activity; IEA:UniProtKB-KW.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0071361; P:cellular response to ethanol; IEA:Ensembl.
DR   GO; GO:1904845; P:cellular response to L-glutamine; IEA:Ensembl.
DR   GO; GO:0006952; P:defense response; IBA:GO_Central.
DR   GO; GO:0022900; P:electron transport chain; IEA:GOC.
DR   GO; GO:0050665; P:hydrogen peroxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0097411; P:hypoxia-inducible factor-1alpha signaling pathway; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IMP:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0034765; P:regulation of monoatomic ion transmembrane transport; IEA:UniProtKB-KW.
DR   GO; GO:0045730; P:respiratory burst; IMP:BHF-UCL.
DR   GO; GO:1904044; P:response to aldosterone; IEA:Ensembl.
DR   GO; GO:1990776; P:response to angiotensin; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0042554; P:superoxide anion generation; IDA:BHF-UCL.
DR   GO; GO:0006801; P:superoxide metabolic process; IDA:BHF-UCL.
DR   CDD; cd06186; NOX_Duox_like_FAD_NADP; 1.
DR   Gene3D; 3.40.50.80; Nucleotide-binding domain of ferredoxin-NADP reductase (FNR) module; 1.
DR   Gene3D; 2.40.30.10; Translation factors; 1.
DR   InterPro; IPR000778; Cyt_b245_heavy_chain.
DR   InterPro; IPR013112; FAD-bd_8.
DR   InterPro; IPR017927; FAD-bd_FR_type.
DR   InterPro; IPR013130; Fe3_Rdtase_TM_dom.
DR   InterPro; IPR013121; Fe_red_NAD-bd_6.
DR   InterPro; IPR039261; FNR_nucleotide-bd.
DR   InterPro; IPR017938; Riboflavin_synthase-like_b-brl.
DR   PANTHER; PTHR11972:SF60; CYTOCHROME B-245 HEAVY CHAIN; 1.
DR   PANTHER; PTHR11972; NADPH OXIDASE; 1.
DR   Pfam; PF08022; FAD_binding_8; 1.
DR   Pfam; PF01794; Ferric_reduct; 1.
DR   Pfam; PF08030; NAD_binding_6; 1.
DR   PRINTS; PR00466; GP91PHOX.
DR   SFLD; SFLDS00052; Ferric_Reductase_Domain; 1.
DR   SFLD; SFLDG01168; Ferric_reductase_subgroup_(FRE; 1.
DR   SUPFAM; SSF52343; Ferredoxin reductase-like, C-terminal NADP-linked domain; 1.
DR   SUPFAM; SSF63380; Riboflavin synthase domain-like; 1.
DR   PROSITE; PS51384; FAD_FR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chronic granulomatous disease;
KW   Direct protein sequencing; Disease variant; Electron transport; FAD;
KW   Flavoprotein; Glycoprotein; Heme; Ion channel; Ion transport; Iron;
KW   Isopeptide bond; Membrane; Metal-binding; NADP; Oxidoreductase;
KW   Phosphoprotein; Reference proteome; Transmembrane; Transmembrane helix;
KW   Transport; Ubl conjugation; Voltage-gated channel.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:3600769"
FT   CHAIN           2..570
FT                   /note="Cytochrome b-245 heavy chain"
FT                   /id="PRO_0000210145"
FT   TOPO_DOM        2..8
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        9..29
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        30..48
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        49..69
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        70..102
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        103..123
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        124..169
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        170..190
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        191..200
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        201..221
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        222..261
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        262..282
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        283..570
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          54..286
FT                   /note="Ferric oxidoreductase"
FT   DOMAIN          287..397
FT                   /note="FAD-binding FR-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00716"
FT   BINDING         101
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000305"
FT   BINDING         115
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000305"
FT   BINDING         209
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000305"
FT   BINDING         222
FT                   /ligand="heme"
FT                   /ligand_id="ChEBI:CHEBI:30413"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000305"
FT   BINDING         338..344
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        132
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        149
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        240
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CROSSLNK        161
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   CROSSLNK        255
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   CROSSLNK        294
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   CROSSLNK        299
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   CROSSLNK        306
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   CROSSLNK        328
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   CROSSLNK        334
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   CROSSLNK        381
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   CROSSLNK        506
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   CROSSLNK        567
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q61093"
FT   VARIANT         18
FT                   /note="W -> C (in CGDX)"
FT                   /id="VAR_047264"
FT   VARIANT         20
FT                   /note="G -> R (in CGDX; dbSNP:rs151344455)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007873"
FT   VARIANT         41
FT                   /note="Y -> D (in CGDX; dbSNP:rs151344453)"
FT                   /evidence="ECO:0000269|PubMed:12139950"
FT                   /id="VAR_025613"
FT   VARIANT         54..55
FT                   /note="Missing (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:11462241"
FT                   /id="VAR_047265"
FT   VARIANT         54
FT                   /note="R -> M (in CGDX; dbSNP:rs151344479)"
FT                   /evidence="ECO:0000269|PubMed:10914676,
FT                   ECO:0000269|PubMed:23910690, ECO:0000269|PubMed:9667376"
FT                   /id="VAR_025614"
FT   VARIANT         54
FT                   /note="R -> S (in CGDX; dbSNP:rs151344456)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007874"
FT   VARIANT         55
FT                   /note="A -> D (in CGDX; dbSNP:rs151344480)"
FT                   /evidence="ECO:0000269|PubMed:10914676,
FT                   ECO:0000269|PubMed:9667376"
FT                   /id="VAR_025615"
FT   VARIANT         57
FT                   /note="A -> E (in CGDX; dbSNP:rs151344481)"
FT                   /evidence="ECO:0000269|PubMed:10914676,
FT                   ECO:0000269|PubMed:8101486, ECO:0000269|PubMed:9667376"
FT                   /id="VAR_008845"
FT   VARIANT         59
FT                   /note="C -> R (in CGDX; dbSNP:rs151344457)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007875"
FT   VARIANT         59
FT                   /note="C -> W (in CGDX; dbSNP:rs151344488)"
FT                   /evidence="ECO:0000269|PubMed:11462241"
FT                   /id="VAR_047266"
FT   VARIANT         101
FT                   /note="H -> R (in CGDX; dbSNP:rs137854591)"
FT                   /evidence="ECO:0000269|PubMed:1710153"
FT                   /id="VAR_002432"
FT   VARIANT         101
FT                   /note="H -> Y (in CGDX; dbSNP:rs137854594)"
FT                   /evidence="ECO:0000269|PubMed:10914676,
FT                   ECO:0000269|PubMed:9856476"
FT                   /id="VAR_007876"
FT   VARIANT         119
FT                   /note="H -> R (in CGDX; dbSNP:rs151344458)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007877"
FT   VARIANT         156
FT                   /note="A -> T (in CGDX; dbSNP:rs137854590)"
FT                   /evidence="ECO:0000269|PubMed:1710153,
FT                   ECO:0000269|PubMed:9585602"
FT                   /id="VAR_002433"
FT   VARIANT         178
FT                   /note="T -> P (in IMD34; dbSNP:rs151344497)"
FT                   /evidence="ECO:0000269|PubMed:21278736"
FT                   /id="VAR_065365"
FT   VARIANT         179
FT                   /note="G -> R (in CGDX; dbSNP:rs151344491)"
FT                   /evidence="ECO:0000269|PubMed:9794433"
FT                   /id="VAR_047267"
FT   VARIANT         193
FT                   /note="S -> F (in CGDX; dbSNP:rs151344493)"
FT                   /evidence="ECO:0000269|PubMed:10089913"
FT                   /id="VAR_047268"
FT   VARIANT         205
FT                   /note="F -> I (in CGDX; dbSNP:rs151344496)"
FT                   /evidence="ECO:0000269|PubMed:8916969"
FT                   /id="VAR_047269"
FT   VARIANT         209
FT                   /note="H -> Q (in CGDX; dbSNP:rs151344459)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007878"
FT   VARIANT         209
FT                   /note="H -> R (in CGDX; dbSNP:rs151344482)"
FT                   /evidence="ECO:0000269|PubMed:10914676"
FT                   /id="VAR_025616"
FT   VARIANT         209
FT                   /note="H -> Y (in CGDX; dbSNP:rs137854587)"
FT                   /evidence="ECO:0000269|PubMed:1710153"
FT                   /id="VAR_002434"
FT   VARIANT         215
FT                   /note="Missing (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:8916969,
FT                   ECO:0000269|PubMed:9111587"
FT                   /id="VAR_007879"
FT   VARIANT         222
FT                   /note="H -> N (in CGDX; dbSNP:rs151344460)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007880"
FT   VARIANT         222
FT                   /note="H -> R (in CGDX; dbSNP:rs151344462)"
FT                   /evidence="ECO:0000269|PubMed:10089913,
FT                   ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007881"
FT   VARIANT         222
FT                   /note="H -> Y (in CGDX; dbSNP:rs151344460)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007882"
FT   VARIANT         223
FT                   /note="G -> L (in CGDX; requires 2 nucleotide
FT                   substitutions; dbSNP:rs151344463 and dbSNP:rs151344464)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007883"
FT   VARIANT         224
FT                   /note="A -> G (in CGDX; dbSNP:rs151344483)"
FT                   /evidence="ECO:0000269|PubMed:10914676"
FT                   /id="VAR_025617"
FT   VARIANT         225
FT                   /note="E -> V (in CGDX; dbSNP:rs151344494)"
FT                   /evidence="ECO:0000269|PubMed:9888386"
FT                   /id="VAR_002435"
FT   VARIANT         231
FT                   /note="Q -> P (in IMD34; dbSNP:rs151344498)"
FT                   /evidence="ECO:0000269|PubMed:21278736"
FT                   /id="VAR_065366"
FT   VARIANT         244
FT                   /note="C -> R (in CGDX; dbSNP:rs151344465)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007884"
FT   VARIANT         244
FT                   /note="C -> S (in CGDX; dbSNP:rs137854589)"
FT                   /evidence="ECO:0000269|PubMed:1710153"
FT                   /id="VAR_002436"
FT   VARIANT         244
FT                   /note="C -> Y (in CGDX; dbSNP:rs137854589)"
FT                   /evidence="ECO:0000269|PubMed:9888386"
FT                   /id="VAR_002437"
FT   VARIANT         298..302
FT                   /note="Missing (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:9794433"
FT                   /id="VAR_047270"
FT   VARIANT         299
FT                   /note="K -> N (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:23910690"
FT                   /id="VAR_071861"
FT   VARIANT         303
FT                   /note="H -> N (in CGDX; completely inhibits NADPH oxidase
FT                   activity; NADPH oxidase assembly is abolished;
FT                   dbSNP:rs137854595)"
FT                   /evidence="ECO:0000269|PubMed:11997083,
FT                   ECO:0000269|PubMed:15338276"
FT                   /id="VAR_016880"
FT   VARIANT         304
FT                   /note="P -> R (in CGDX; reduces NADPH oxidase activity to
FT                   4% of wild-type; translocation to the membrane of the
FT                   phagosome is only attenuated; dbSNP:rs137854596)"
FT                   /evidence="ECO:0000269|PubMed:11997083,
FT                   ECO:0000269|PubMed:15338276"
FT                   /id="VAR_016881"
FT   VARIANT         307
FT                   /note="T -> P (in CGDX; dbSNP:rs151344489)"
FT                   /evidence="ECO:0000269|PubMed:11462241"
FT                   /id="VAR_047271"
FT   VARIANT         309
FT                   /note="E -> K (in CGDX; dbSNP:rs151344466)"
FT                   /evidence="ECO:0000269|PubMed:10914676,
FT                   ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007885"
FT   VARIANT         315
FT                   /note="Missing (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_047272"
FT   VARIANT         322
FT                   /note="G -> E (in CGDX; dbSNP:rs151344467)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007886"
FT   VARIANT         325
FT                   /note="I -> F (in CGDX; dbSNP:rs151344468)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007887"
FT   VARIANT         333
FT                   /note="S -> P (in CGDX; dbSNP:rs151344469)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007888"
FT   VARIANT         338
FT                   /note="H -> D (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:23910690"
FT                   /id="VAR_071862"
FT   VARIANT         338
FT                   /note="H -> Y (in CGDX; dbSNP:rs151344484)"
FT                   /evidence="ECO:0000269|PubMed:10089913,
FT                   ECO:0000269|PubMed:10914676"
FT                   /id="VAR_025618"
FT   VARIANT         339
FT                   /note="P -> H (in CGDX; dbSNP:rs151344470)"
FT                   /evidence="ECO:0000269|PubMed:10089913,
FT                   ECO:0000269|PubMed:10914676, ECO:0000269|PubMed:23910690,
FT                   ECO:0000269|PubMed:7927345, ECO:0000269|PubMed:9585602,
FT                   ECO:0000269|PubMed:9667376"
FT                   /id="VAR_002438"
FT   VARIANT         342
FT                   /note="L -> Q (in CGDX; dbSNP:rs151344495)"
FT                   /evidence="ECO:0000269|PubMed:8916969"
FT                   /id="VAR_047273"
FT   VARIANT         344
FT                   /note="S -> F (in CGDX; dbSNP:rs151344485)"
FT                   /evidence="ECO:0000269|PubMed:10914676,
FT                   ECO:0000269|PubMed:23910690, ECO:0000269|PubMed:9667376"
FT                   /id="VAR_025619"
FT   VARIANT         356
FT                   /note="R -> P (in CGDX; dbSNP:rs151344471)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007889"
FT   VARIANT         364
FT                   /note="G -> R (in dbSNP:rs141756032)"
FT                   /evidence="ECO:0000269|PubMed:10089913,
FT                   ECO:0000269|PubMed:12139950"
FT                   /id="VAR_025620"
FT   VARIANT         389
FT                   /note="G -> A (in CGDX; dbSNP:rs137854586)"
FT                   /evidence="ECO:0000269|PubMed:1710153"
FT                   /id="VAR_002439"
FT   VARIANT         389
FT                   /note="G -> E (in CGDX; dbSNP:rs137854586)"
FT                   /evidence="ECO:0000269|PubMed:10914676"
FT                   /id="VAR_025621"
FT   VARIANT         405
FT                   /note="M -> R (in CGDX; dbSNP:rs151344472)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007890"
FT   VARIANT         408
FT                   /note="G -> E (in CGDX; dbSNP:rs151344474)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007891"
FT   VARIANT         408
FT                   /note="G -> R (in CGDX; dbSNP:rs151344473)"
FT                   /evidence="ECO:0000269|PubMed:18773283,
FT                   ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007892"
FT   VARIANT         409
FT                   /note="A -> G (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:27666509"
FT                   /id="VAR_078386"
FT   VARIANT         412
FT                   /note="G -> E (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:23910690"
FT                   /id="VAR_071863"
FT   VARIANT         415
FT                   /note="P -> H (in CGDX; dbSNP:rs137854585)"
FT                   /evidence="ECO:0000269|PubMed:2556453,
FT                   ECO:0000269|PubMed:9585602"
FT                   /id="VAR_002440"
FT   VARIANT         415
FT                   /note="P -> L (in CGDX; dbSNP:rs137854585)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007893"
FT   VARIANT         420
FT                   /note="L -> P (in CGDX; dbSNP:rs151344486)"
FT                   /evidence="ECO:0000269|PubMed:10914676"
FT                   /id="VAR_025622"
FT   VARIANT         422
FT                   /note="S -> P (in CGDX; dbSNP:rs151344475)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007894"
FT   VARIANT         453
FT                   /note="W -> R (in CGDX; dbSNP:rs151344476)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007895"
FT   VARIANT         472
FT                   /note="G -> S (in dbSNP:rs13306300)"
FT                   /id="VAR_047274"
FT   VARIANT         488
FT                   /note="A -> D (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:22125116"
FT                   /id="VAR_068012"
FT   VARIANT         500
FT                   /note="D -> E (in CGDX)"
FT                   /evidence="ECO:0000269|PubMed:22125116"
FT                   /id="VAR_068013"
FT   VARIANT         500
FT                   /note="D -> G (in CGDX; dbSNP:rs137854593)"
FT                   /evidence="ECO:0000269|PubMed:8182143"
FT                   /id="VAR_002441"
FT   VARIANT         505
FT                   /note="L -> R (in CGDX; dbSNP:rs151344490)"
FT                   /evidence="ECO:0000269|PubMed:11462241"
FT                   /id="VAR_047275"
FT   VARIANT         516
FT                   /note="W -> C (in CGDX; dbSNP:rs151344477)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007896"
FT   VARIANT         516
FT                   /note="W -> R (in CGDX; dbSNP:rs151344487)"
FT                   /evidence="ECO:0000269|PubMed:10914676"
FT                   /id="VAR_025623"
FT   VARIANT         517
FT                   /note="D -> E (in dbSNP:rs151344452)"
FT                   /evidence="ECO:0000269|PubMed:12139950"
FT                   /id="VAR_025624"
FT   VARIANT         534
FT                   /note="V -> D (in CGDX; dbSNP:rs151344478)"
FT                   /evidence="ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007897"
FT   VARIANT         537
FT                   /note="C -> R (in CGDX; dbSNP:rs151344454)"
FT                   /evidence="ECO:0000269|PubMed:12139950,
FT                   ECO:0000269|PubMed:9585602"
FT                   /id="VAR_007898"
FT   VARIANT         546
FT                   /note="L -> P (in CGDX; dbSNP:rs151344492)"
FT                   /evidence="ECO:0000269|PubMed:10089913"
FT                   /id="VAR_047276"
FT   CONFLICT        14
FT                   /note="V -> A (in Ref. 6 and 4)"
FT                   /evidence="ECO:0000305"
FT   HELIX           393..398
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   STRAND          401..409
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   HELIX           410..412
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   HELIX           413..429
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   STRAND          438..446
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   TURN            448..451
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   HELIX           452..467
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   STRAND          473..480
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   STRAND          509..512
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   HELIX           516..526
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   STRAND          531..538
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   HELIX           540..552
FT                   /evidence="ECO:0007829|PDB:3A1F"
FT   STRAND          562..566
FT                   /evidence="ECO:0007829|PDB:3A1F"
SQ   SEQUENCE   570 AA;  65336 MW;  7E84051BD4000CE3 CRC64;
     MGNWAVNEGL SIFVILVWLG LNVFLFVWYY RVYDIPPKFF YTRKLLGSAL ALARAPAACL
     NFNCMLILLP VCRNLLSFLR GSSACCSTRV RRQLDRNLTF HKMVAWMIAL HSAIHTIAHL
     FNVEWCVNAR VNNSDPYSVA LSELGDRQNE SYLNFARKRI KNPEGGLYLA VTLLAGITGV
     VITLCLILII TSSTKTIRRS YFEVFWYTHH LFVIFFIGLA IHGAERIVRG QTAESLAVHN
     ITVCEQKISE WGKIKECPIP QFAGNPPMTW KWIVGPMFLY LCERLVRFWR SQQKVVITKV
     VTHPFKTIEL QMKKKGFKME VGQYIFVKCP KVSKLEWHPF TLTSAPEEDF FSIHIRIVGD
     WTEGLFNACG CDKQEFQDAW KLPKIAVDGP FGTASEDVFS YEVVMLVGAG IGVTPFASIL
     KSVWYKYCNN ATNLKLKKIY FYWLCRDTHA FEWFADLLQL LESQMQERNN AGFLSYNIYL
     TGWDESQANH FAVHHDEEKD VITGLKQKTL YGRPNWDNEF KTIASQHPNT RIGVFLCGPE
     ALAETLSKQS ISNSESGPRG VHFIFNKENF
//
